I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Hashimoto\'s thyroiditis (HT), also called autoimmune thyroiditis, is an autoimmune disease, and clinically, it is the most common thyroid-related inflammation. Genetic factors, especially the susceptibility genes, play an important role in the pathogenesis of this disease. Many immune and proinflammatory mediators have been identified to be associated with susceptibility to HT. Among them, interleukin-23 receptor (*IL-23R*) gene has been shown to be associated with various autoimmune diseases and regulate the expression of genes involved in inflammation. The *IL-23R* gene is located on human chromosome 1p31.3, and its open reading frame is composed of 12 exons with total length around 92 kb. The single nucleotide polymorphisms (SNPs) sites of *IL-23R* are commonly located on the promoter, exon, or intron regions of the *IL-23R* gene. IL-23 is generally expressed on the cell surface of T lymphocytes, natural killer cells, and dendritic cells.\[[@ref1][@ref2]\] IL-23R, a member of hemopoietin receptor superfamily, is the specific component of the heterodimeric receptor complex for IL-23 signaling cascade. Therefore, IL-23 and IL-23R signaling pathway plays a significant role in immune regulation. It has been demonstrated that *IL-23R* gene SNPs are strongly correlated with various chronic inflammatory diseases including Crohn\'s disease,\[[@ref3]\] rheumatoid arthritis,\[[@ref4]\] ankylosing spondylitis (AS),\[[@ref5]\] and Behcet\'s disease (BD). However, the linkage between *IL-23R* SNPs and susceptibility to HT has not been well-established. In the present study, we aimed to elucidate whether the polymorphisms of the *IL-23R* gene contribute to the development of HT in Chinese Han population of Shandong by analyzing two SNPs rs17375018 and rs7517847 of *IL-23R* gene, and highlight the potential role of *IL-23R* polymorphisms in the pathogenesis of HT.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

A total of 145 HT patients from First People\'s Hospital of Jining between February 2010 to October 2013 and 150 healthy controls were recruited in this case--control cohort study. All patients were of Chinese Han ethnic origin, and the control population consisted of unrelated healthy individuals, they were age-, sex-, and ethnicity-matched with the patients. All the study participants provided written informed consent, and the study protocols were approved by Ethical Committee of First People\'s Hospital of Jining. The HT patients were diagnosed according to the documented clinical and biochemical hypothyroidism requiring thyroid hormone replacement therapy and exhibited autoantibodies against thyroid peroxidase with or without antibodies against thyroglobulin (TG).\[[@ref6]\] The clinical characteristics of the HT patients were recorded at the time of diagnosis. Clinical features and demographic characteristics of two groups were summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical features and demographic characteristics of the study population

  Characteristics             HT group (*n* = 145)   Control group (*n* = 150)
  --------------------------- ---------------------- ---------------------------
  Male/female, *n*            11/134                 15/135
  Age, years, mean (range)    38.02 (15--67)         42.19 (18--63)
  TSH, mIU/L, mean ± SD       53.60 ± 30.94          2.01 ± 0.78
  FT~4~, pmol/L, mean ± SD    2.85 ± 0.56            3.46 ± 0.64
  FT~3~, pmol/L, mean ± SD    0.64 ± 0.06            0.95 ± 0.08
  Anti-TG, U/ml, mean ± SD    931.46 ± 540.22        \<115
  Anti-TPO, U/ml, mean ± SD   401.62 ± 229.56        \<10
  TRAb, ng/L, mean ± SD       13.2 ± 3.77            12.1 ± 1.15

TSH: Thyroid stimulating hormone; FT~4~: Free thyroxine; FT~3~: Free triiodothyronine; Anti-TG: Anti-thyroglobulin autoantibodies; Anti-TPO: Anti-thyroid peroxidase antibodies; TRAb: Thyrotrophin receptor antibody; SD: Standard deviation.

Single nucleotide polymorphism selection and genotyping {#sec2-2}
-------------------------------------------------------

The rs17375018 and rs7517847 were selected as candidate SNPs, which were demonstrated earlier by another group of researchers to be associated with certain immune-related diseases.\[[@ref7]\] A 5-μl reaction mixture, which consisted of 2.5 μl Premix Taq, 20 pmol primers, and 0.2 μg of genomic deoxyribonucleic acid, was amplified by polymerase chain reaction (PCR). The primers used in this study were presented in [Table 2](#T2){ref-type="table"}. The conditions were as follows: Initial denaturation at 95°C for 5 min, followed by 38 cycles of denaturation at 94°C for 30 s, annealing at different temperatures (55°C for rs17375018, and 58°C for rs7517847) for 30 s, extension at 72°C for 30 s, and a final extension at 72°C for 5 min. These SNPs were genotyped by PCR-restriction fragment length polymorphism analysis. The PCR products of the rs17375018 and rs7517847 polymorphisms were digested overnight with BsurI (New England Biolabs, Inc., Ontario, Canada) and Ec0147I (New England Biolabs, Inc., Ontario, Canada) restriction enzymes \[[Table 2](#T2){ref-type="table"}\] in a 10-μl reaction volume. Digestion products were visualized on a 3.5% agarose gel and stained with Gold View (SBS Genetech, Beijing, China) \[[Figure 1](#F1){ref-type="fig"}\]. Direct sequencing was performed by Invitrogen Biotechnology Company (Guangdong, China) using randomly selected subjects (20% of all samples) to validate the method used in this study. Results were completely consistent.

###### 

Primers and restriction enzymes used for RFLP analysis of *IL-23R* gene

  SNPs         Primers                    Restriction enzyme
  ------------ -------------------------- --------------------
  rs17375018   5'-TTTTTCCCATCT            BsurI
               TCTTTCTTAA-3'(forward)     
               5'-CGCCCAGCCCT             
               CTTCTCTAATT-3'(reverse)    
  rs7517847    5'-CCTTTCACCTAT            Ec0147I
               TCCCAAGGCC-3' (forward)    
               5'-GGGCCTAGGAG             
               ACAGCCCATAA-3' (reverse)   

SNPs: Single nucleotide polymorphisms; RFLP: Restriction fragment length polymorphism.

![Restriction enzyme digestion results of rs17375018 and rs7517847. M: Generuler 50 bp deoxyribonucleic acid ladder; Lane 1, 4: rs7517847 TT genotype; Lane 2, 5: rs7517847 GG genotype; Lane 3, 6: rs7517847 TG genotype; Lane 7, 10: rs7375018 GG genotype; Lane 8, 11: rs7375018 AA genotype; Lane 9, 12: rs7375018 GA genotype.](CMJ-128-2050-g001){#F1}

Statistical analysis {#sec2-3}
--------------------

Hardy-Weinberg equilibrium was performed using Chi-square test. Genotype frequencies were estimated by direct counting. Allele and genotype frequencies were compared between patients and healthy controls by the Chi-square test. All normally distributed data were shown as mean ± standard deviation (SD). All data analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). A *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Hardy-Weinberg equilibrium analysis was performed for two *IL-23R* genetic variants in the HT and control groups. Results of Hardy--Weinberg genetic equilibrium test were shown in [Table 3](#T3){ref-type="table"}. The distribution of both genotypic frequencies and allelic frequencies of the two tested IL-23 polymorphisms was shown in [Table 4](#T4){ref-type="table"}. The results showed that there were significant differences between patients with HT and controls concerning the frequencies of rs17375018. The frequencies of the rs17375018 GG genotype and G allele in patients with HT were significantly increased compared with healthy controls (*P* = 0.034 and *P* = 0.013, respectively). There was no difference concerning the frequencies of the rs7517847 SNP between the HT and control groups.

###### 

Hardy--Weinberg genetic equilibrium test results of rs17375018 and rs7517847

  SNPs         Genotype allele   HT group   Control group                        
  ------------ ----------------- ---------- --------------- ------- ---- ------- -------
  rs17375018   AA                6          7.51            0.476   16   15.36   0.810
               GA                54         50.97                   64   65.28   
               GG                85         86.51                   70   69.36   
  rs7517847    TT                51         51.60           0.836   53   54.60   0.585
               GT                71         69.79                   75   71.79   
               GG                23         23.60                   22   23.60   

HT: Hashimoto\'s thyroiditis; SNPs: Single nucleotide polymorphisms.

###### 

Frequencies of alleles and genotypes of *IL-23R* polymorphisms in HT patients and healthy controls

  SNPs         Genotype Allele   HT group, *n* (%) (*n* = 145)   Control group, *n* (%) (*n* = 150)   *χ*^2^   *P*     *OR* (95% *CI*)
  ------------ ----------------- ------------------------------- ------------------------------------ -------- ------- ----------------------
  rs17375018   AA                6 (4.2)                         16 (10.7)                                             0.626 (0.434--0.903)
               GA                54 (37.2)                       64 (42.7)                                             
               GG                85 (58.6)                       70 (46.6)                            6.762    0.034   
               A                 66 (22.8)                       96 (32.0)                                             
               G                 224 (77.2)                      204 (68.0)                           6.322    0.013   
  rs7517847    TT                51 (35.2)                       53 (35.3)                                             1.029 (0.740--1.430)
               GT                71 (49.0)                       75 (50.0)                            0.086    0.958   
               GG                23 (15.8)                       22 (14.7)                            0.028    0.867   
               T                 173 (59.7)                      181 (60.3)                                            
               G                 117 (40.3)                      119 (39.7)                                            

HT: Hashimoto\'s thyroiditis; SNPs: Single nucleotide polymorphisms; *OR*: Odds ratio; *CI*: Confidence interval.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Hashimoto\'s thyroiditis is a common autoimmune inflammatory disease, and TG and thyroid peroxidase antibody has been detected in HT patients. Pathology of this disease mainly includes atrophy and damage of thyroid follicular epithelial cells. Previous studies have shown that IL-17 secreted by Th17 cells is involved in the inflammatory damage, and IL-17 production is regulated by many cytokines including IL-6 and IL-23.\[[@ref8][@ref9]\] It is known that IL-23 can promote inflammation by regulating various proinflammatory cytokines including IL-17, IL-6, IL-8, and tumor necrosis factor (TNF)-α, and maintain the amplification and stability of the Th17 cells.\[[@ref10]\] Thus, we hypothesized that the IL-23-IL-23R signaling pathway may contribute to the pathogenesis of HT. The interaction of IL-23R with its ligand, IL-23, can promote the differentiation of IL-17, which is known to be involved in many chronic inflammatory diseases.\[[@ref11]\] Therefore, IL-23R is critical in the control of the biological activity of IL-23. So far, the association between IL-23R and susceptibility to HT has not been clearly established. The present study demonstrated that only rs17375018 was associated with the risk of HT. The IL-23R rs17375018 allele frequency of G in HT group was significantly higher than that in the healthy control group, suggesting that the GG genotype might be a susceptible gene locus for HT by acting its effect on target gene transcription. Some similar studies in Japanese\[[@ref12]\] and Croatian population\[[@ref13]\] have reported the different conclusions, which suggested the racial differences in the relationship between gene polymorphism and diseases.

It is known that IL-23R is a type I transmembrane protein and can lead to activation of downstream molecules Jak2 and Tyk2 when its extracellular region is combined with IL-23. Two signal transducers and activators of transcription (STAT) can generate a dimer, and the phosphorylated STATs dimer can move into the nucleus to target gene activation.\[[@ref14]\] SNPs in the *IL-23R* gene cause changes in messenger ribonucleic acid (mRNA) splicing factor and coded amino acid sequence, thus affecting the gene expression and protein function. The rs17375018 is located in the inner segment of *IL-23R* gene. It can be speculated that the rs17375018 G allele can effectively activate their downstream molecules leading to the activations of target genes in the pathogenesis of HT. Thus, activation of IL-23R can promote the differentiation of Th1 cells into Th17 cells subgroup;\[[@ref15]\] and it can increase the release of IL-17, TNF-α, and inflammatory factors, thus to participate in the chronic inflammatory process of HT. Interestingly, Jiang *et al*.\[[@ref7]\] reported that a potential transcription factor binding site for sp-1 existed in the rs17375018 G allele, but not in the rs17375018 A allele. It has been shown that sp-1 can suppress the expression of IL-10, resulting in the enhancement of inflammation.\[[@ref16]\] However, some studies showed an increased level of IL-10 in patients with BD.\[[@ref17][@ref18]\] These discrepant results may partly be explained by the fact that the IL-10 serum level is profoundly influenced by disease activity and medicines used for treatment. Future studies are needed to validate the molecular mechanisms involved in HT.

Recently, some studies showed the associations between rs7517847 gene polymorphism and inflammatory bowel disease, allergic rhinitis,\[[@ref19]\] AS,\[[@ref20]\] and other autoimmune diseases. These studies suggested that the intronic polymorphism rs7517847 might exert its influence by regulating the specific splicing of the gene.\[[@ref21]\] The rs7517847 T → G change may affect mRNA length and protein product.\[[@ref22]\] However, our study indicated that the polymorphism of rs7517847 had no significant difference between the HT and control groups. This might be related to differences in sample population, ethnicity, geography, and sample size. Thus, future study with a larger sample size is need to further validate this relationship.

In conclusion, this study demonstrated that polymorphism of *IL-23R* gene rs17375018 is highly associated with HT in Chinese Han population of Shandong, suggesting that *IL-23R* gene polymorphism (rs17375018 G) may play a critical role in susceptibility to HT. The GG genotype and G allele of rs17375018 were predisposing factors for HT. The G allele of rs17375018 may be a potential therapeutic target for HT in Chinese Han population. In the future, the biological function of rs17375018 needs to be further explored, it is necessary to clarify whether the loci associated with HT identified in the present study and other studies are only markers or causative variants.
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